Provided by Tiger Fintech (Singapore) Pte. Ltd.

BioRestorative Therapies, Inc.

1.65
-0.0550-3.24%
Post-market: 1.660.0141+0.86%16:04 EDT
Volume:156.27K
Turnover:261.73K
Market Cap:12.35M
PE:-1.11
High:1.75
Open:1.70
Low:1.61
Close:1.70
Loading ...

BioRestorative Therapies Inc. Unveils Investor Presentation on Regenerative Medicine Innovations

Reuters
·
27 Jun

BioRestorative Therapies announces $2M share repurchase program

TIPRANKS
·
17 Jun

Promising Outlook for BioRestorative Therapies: Buy Rating Supported by Positive BRTX-100 Data and FDA Fast Track Designation

TIPRANKS
·
17 Jun

BioRestorative Therapies Says BRTX-100 Improved Function in Phase 2 Chronic Lumbar Disc Disease Trial

MT Newswires Live
·
13 Jun

BRIEF-BioRestorative Reports Compelling Preliminary Data For FDA-Fast-Tracked BRTX-100

Reuters
·
13 Jun

BioRestorative Therapies reports preliminary data from Phase 2 trial of BRTX-100

TIPRANKS
·
13 Jun

BioRestorative Therapies appoints Sandy Lipkins for business development

TIPRANKS
·
10 Jun

BioRestorative Therapies Inc. Unveils Investor Presentation on Regenerative Medicine Advancements

Reuters
·
28 May

Roth MKM Sticks to Their Buy Rating for BioRestorative Therapies (BRTX)

TIPRANKS
·
18 May

BioRestorative Therapies Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
16 May

BioRestorative Therapies Q1 EPS $(0.64) Misses $(0.33) Estimate, Sales $25.00K Miss $380.00K Estimate

Benzinga
·
15 May

BioRestorative Therapies Inc expected to post a loss of 32 cents a share - Earnings Preview

Reuters
·
10 May

BioRestorative to Participate in Benzinga All-Access Show Today to Discuss Recent Achievements of Key Clinical & Regulatory Milestones, and Highlight Commercial Opportunities

GlobeNewswire
·
15 Apr

BRIEF-BioRestorative confirms no material impact from reciprocal tariffs

Reuters
·
10 Apr

BioRestorative Confirms No Material Impact from Reciprocal Tariffs; All BRTX-100 Production & Manufacturing Performed in the United States

GlobeNewswire
·
10 Apr

BioRestorative Therapies Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St.
·
29 Mar

BioRestorative Therapies Q4 2024 GAAP EPS $(0.20) Beats $(0.28) Estimate, Sales $43.300K Miss $475.000K Estimate

Benzinga
·
28 Mar

BioRestorative Therapies Reports 2024 Financial Results and Provides Business Update

GlobeNewswire
·
28 Mar

BioRestorative Therapies Inc expected to post a loss of 28 cents a share - Earnings Preview

Reuters
·
26 Mar

BioRestorative Therapies to Report 2024 Financial Results and Host Conference Call on March 27, 2025

GlobeNewswire
·
21 Mar